Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Curr Protoc. 2021 Sep;1(9):e236. doi: 10.1002/cpz1.236.
Human artificial chromosomes (HACs) are considered promising tools for gene delivery, functional analyses, and gene therapy. HACs have the potential to overcome many of the problems caused by the use of viral-based gene transfer systems, such as limited cloning capacity, lack of copy number control, and insertional mutagenesis during integration into host chromosomes. The recently developed alphoid -HAC has an advantage over other HAC vectors because it can be easily eliminated from dividing cells by inactivation of its conditional kinetochore. This provides a unique control mechanism to study phenotypes induced by a gene or genes carried on the HAC. The alphoid -HAC has a single gene acceptor loxP site that allows insertion of an individual gene of interest or a cluster of genes of up to several Mb in size in Chinese hamster ovary (CHO) hybrid cells. The HACs carrying chromosomal copies of genes can then be transferred from these donor CHO cells to different recipient cells of interest via microcell-mediated chromosome transfer (MMCT). Here, we describe a detailed protocol for loading a gene of interest into the alphoid -HAC vector and for the subsequent transfer of the HAC to recipient cells using an improved MMCT protocol. The original MMCT protocol includes treatment of donor cells with colcemid to induce micronucleation, wherein the HAC becomes surrounded with a nuclear membrane. That step is followed by disarrangement of the actin cytoskeleton using cytochalasin B to help induce microcell formation. The updated MMCT protocol, described here, features the replacement of colcemid and cytochalasin B with TN16 + griseofulvin and latrunculin B, respectively, and the use of collagen/laminin surface coating to promote attachment of metaphase cells to plates during micronuclei induction. These modifications increase the efficiency of HAC transfer to recipient cells ten fold. The improved MMCT protocol has been successfully tested on several recipient cell lines, including human mesenchymal stem cells and mouse embryonic stem cells. © 2021 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Insertion of a BAC containing a gene of interest into a single loxP loading site of alphoid -HAC in hamster CHO cells Basic Protocol 2: Microcell-mediated chromosome transfer from donor hamster CHO cells to mammalian cells.
人类人工染色体 (HAC) 被认为是基因传递、功能分析和基因治疗的有前途的工具。HAC 有可能克服使用基于病毒的基因转移系统引起的许多问题,例如克隆容量有限、缺乏拷贝数控制以及在整合到宿主染色体时的插入诱变。最近开发的α- HAC 相对于其他 HAC 载体具有优势,因为它可以通过失活其条件性动粒而从分裂细胞中轻易消除。这为研究 HAC 上携带的单个基因或基因引起的表型提供了独特的控制机制。α- HAC 具有单个基因接受体 loxP 位点,允许在 CHO 杂种细胞中插入单个感兴趣的基因或多达几个 Mb 大小的基因簇。然后可以通过微细胞介导的染色体转移 (MMCT) 将携带染色体拷贝的 HAC 从这些供体 CHO 细胞转移到不同的感兴趣的受体细胞。在这里,我们描述了一种将感兴趣的基因加载到α- HAC 载体中并通过改进的 MMCT 方案将 HAC 转移到受体细胞中的详细方案。原始的 MMCT 方案包括用秋水仙素处理供体细胞以诱导微核形成,其中 HAC 被核膜包围。然后使用细胞松弛素 B 扰乱肌动蛋白细胞骨架,以帮助诱导微细胞形成。这里描述的更新的 MMCT 方案的特点是分别用 TN16+灰黄霉素和 latrunculin B 代替秋水仙素和细胞松弛素 B,以及使用胶原/层粘连蛋白表面涂层在微核诱导期间促进中期细胞附着到平板上。这些修改将 HAC 转移到受体细胞的效率提高了十倍。改良的 MMCT 方案已成功应用于几种受体细胞系,包括人间充质干细胞和小鼠胚胎干细胞。© 2021 作者。Wiley Periodicals LLC 出版的《当代协议》。基本方案 1:将包含感兴趣基因的 BAC 插入仓鼠 CHO 细胞中α- HAC 的单个 loxP 加载位点中 基本方案 2:从供体仓鼠 CHO 细胞到哺乳动物细胞的微细胞介导的染色体转移。